We will be attending the RSVVW’26 Conference in Rome, taking place from 17 – 20 February 2026. RSVVW’26 is a leading global conference dedicated to advancing research and development in respiratory syncytial virus (RSV) preventive and therapeutic interventions, bringing together scientists, clinicians, industry experts, and decision-makers from around the world.
As a world leader in human viral challenge trials and an expert in respiratory disease models, hVIVO’s participation underscores our commitment to driving innovation in RSV and broader respiratory disease research. Our state-of-the-art human challenge models, including the only commercially available RSV challenge model, and our integrated virology and immunology services uniquely position us to support the acceleration of vaccines and antiviral therapeutics, making RSVVW’26 a perfect forum to share insights, collaborate with the global scientific community, and highlight how our services can help address critical unmet needs in RSV development.
At hVIVO, we are a full-service early-phase contract research organisation (CRO) offering end-to-end drug development services from preclinical consultancy through to Phase III clinical trials. Our team brings together strategic insight and operational expertise to deliver a variety of clinical study types, including first-in-human and human challenge trials.
hVIVO, the experts in human challenge trials.
With 13+ fully characterised challenge study models, conducted 80+ studies with 5000+ subjects inoculated hVIVO has unparalleled experience in human challenge trials.
Our specialist infectious disease laboratory provides specialist expertise in virology, immunology, and molecular biology to support the development of innovative vaccines and therapeutics. Operating within state-of-the-art Biosafety Level 2 and 3 facilities, we deliver high-quality sample analysis and data outputs that empower our clients to achieve proof of concept or drive breakthrough discoveries in the pathology and treatment of diseases with significant unmet medical needs.
Our capabilities span assay development, transfer, and optimisation across immunology, molecular, and cell-based platforms, with extensive options for sample matrix and stability testing. Every assay is validated in line with FDA, EMA, and ICH guidelines, ensuring the highest scientific and regulatory standards. Our lab services play a critical role in our end-to-end early clinical development services, helping a global network of biopharma partners accelerate innovation.
At hVIVO we also offer our sites as a service. All our sites have integrated laboratory or laboratory-processing facilities, including our cutting edge 50-bed quarantine facility in London, with our specialist virology and immunology laboratory on site. Together, our clinical trial sites provide access to a huge participant populations with the capacity to screen over 1000 participants a week.
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
